A comprehensive review published in Frontiers in Drug Discovery examines the current landscape of Nipah virus vaccine research, synthesizing evidence from epidemiology, viral pathogenesis, immunobiology, and translational vaccine science. The authors systematically evaluated the major vaccine platforms now in play, including recombinant soluble glycoprotein subunit vaccines, viral-vectored approaches, mRNA-based constructs, DNA vaccines, virus-like particles, and nanoparticle-based systems. Their analysis also covers emerging strategies such as immunoinformatic-guided multi-epitope design and rapid-response manufacturing, situating these advances within global preparedness frameworks like the Coalition for Epidemic Preparedness Innovations 100 Days Mission.

The biological case for vaccination rests on the virus’s entry mechanism and the immune targets it exposes. NiV gains access to host cells through two envelope glycoproteins: the attachment glycoprotein G, which binds ephrin-B2 and ephrin-B3 receptors on host cell surfaces, and the fusion glycoprotein F, which drives membrane fusion. These surface proteins are the principal antigens targeted by neutralizing antibodies, making them the centerpiece of nearly every vaccine platform under development. Subunit vaccines typically deliver a recombinant soluble version of the G glycoprotein, engineered to present native-like epitopes without infectious material, while viral-vectored and nucleic acid platforms instruct host cells to produce the antigen in situ, eliciting both humoral and cellular immune responses.

Preclinical evidence across animal models has been central to advancing these candidates. Hamsters, ferrets, and African green monkeys have served as the primary models because they reproduce key features of human NiV disease, including severe respiratory illness and neurologic involvement. Subunit vaccines formulated with adjuvants have demonstrated robust neutralizing antibody titers and protection against lethal challenge in nonhuman primates. Viral-vectored candidates, including those based on measles virus, vesicular stomatitis virus, and adenoviral backbones, have shown single-dose protection in animal studies, an attribute considered valuable for outbreak settings where rapid immunization may be required. mRNA and DNA platforms have likewise generated strong immunogenicity data in preclinical systems, benefiting from the speed and scalability these technologies demonstrated during the COVID-19 pandemic.

Several candidates have now crossed the translational threshold into early-phase clinical evaluation. Subunit, viral-vectored, and mRNA-based platforms have progressed from experimental stages to human trials, marking a significant shift from purely preclinical exploration to clinical translation. Phase 1 studies are designed primarily to establish safety, tolerability, and immunogenicity signals, and early results from these trials are informing dose selection and regimen design for later-stage development. The movement of multiple candidates into clinical testing reflects both scientific momentum and renewed investment driven by pandemic preparedness initiatives that treat NiV as a prototype pathogen for regional outbreak response.

Yet the review underscores persistent obstacles that complicate the path to licensure. Chief among them is the absence of validated immune correlates of protection. Without a defined immunologic benchmark, such as a specific neutralizing antibody titer reliably predictive of protection, regulators and developers cannot approve vaccines on immunogenicity data alone, nor can they bridge efficacy findings across populations or animal models with confidence. This gap forces reliance on conventional efficacy trials, which are difficult to conduct for a pathogen whose outbreaks are sporadic, geographically localized, and hard to anticipate. The unpredictability of NiV emergence means that trial sites may not align with outbreak timing, and case numbers during any given epidemic may be too small to power a traditional endpoint-driven study.

Antigenic variability presents a further complication. Circulating NiV strains in Bangladesh and Malaysia differ genetically and antigenically, raising questions about whether a vaccine designed against one strain will confer adequate protection against others. The virus also infects a broad range of animal hosts, including bats as the natural reservoir and pigs and horses as intermediate or amplifying hosts, which complicates both ecological control and the design of One Health interventions. Human-to-human transmission, documented particularly in Bangladesh through close contact with infected patients, adds another layer of public health urgency and underscores the need for vaccines that interrupt not only spillover but also onward spread.

To address these challenges, the field is increasingly turning to computational and platform-based innovations. Immunoinformatic-guided multi-epitope vaccine design uses predictive algorithms to identify B cell and T cell epitopes across viral proteins, enabling the construction of immunogens that maximize coverage across circulating strains. These approaches can compress early discovery timelines and prioritize candidates with broad potential reactivity. Rapid-response manufacturing strategies, including mRNA and other nucleic acid platforms, allow vaccine sequences to be updated quickly in response to new viral variants or outbreak strains, aligning with the CEPI 100 Days Mission, which aims to develop new vaccines against epidemic threats within approximately 100 days of pathogen identification.

The review also situates NiV vaccine development within the broader architecture of global preparedness. Because NiV shares key biological features with other henipaviruses, such as Hendra virus, advances in NiV vaccinology may inform countermeasures against related pathogens, and vice versa. The Hendra virus vaccine for horses, developed using a soluble G glycoprotein subunit strategy, provided an early proof of concept that henipavirus glycoproteins can elicit protective immunity, and this legacy continues to shape NiV candidate design. Cross-platform learning, from adjuvant selection to vector choice to manufacturing scale-up, is accelerating progress across the henipavirus field as a whole.

Looking ahead, the authors conclude that continued advances in translational vaccinology, computational vaccine design, and coordinated global preparedness are likely to accelerate the arrival of a licensed NiV vaccine. The convergence of multiple platforms in clinical testing, the maturation of structure-guided and epitope-based immunogen design, and the institutional momentum generated by the 100 Days Mission collectively suggest that the field is closer than it has ever been to closing a gap that has persisted since the virus first emerged. Still, translating preclinical promise into licensed products will require sustained investment, innovative trial designs capable of operating in outbreak-prone regions, and international collaboration to ensure that vaccines reach the communities where the burden of Nipah virus disease is greatest.

Subject of Research: Development and clinical translation of vaccines against Nipah virus

Article Title: Nipah virus vaccine development: current platforms, preclinical evidence, and clinical translation

Article References: Nipah virus vaccine development: current platforms, preclinical evidence, and clinical translation. (n.d.). https://doi.org/10.3389/fddsv.2026.1906594

Image Credits: AI Generated

DOI: 10.3389/fddsv.2026.1906594

Keywords: Nipah virus, Henipavirus, vaccine development, subunit vaccines, viral vectors, mRNA vaccines, immune correlates of protection, outbreak preparedness, CEPI 100 Days Mission, epitope-based vaccine design, zoonotic disease, clinical trials